AR054231A1 - Composiciones farmaceuticas - Google Patents
Composiciones farmaceuticasInfo
- Publication number
- AR054231A1 AR054231A1 AR20060100713A ARP060100713A AR054231A1 AR 054231 A1 AR054231 A1 AR 054231A1 AR 20060100713 A AR20060100713 A AR 20060100713A AR P060100713 A ARP060100713 A AR P060100713A AR 054231 A1 AR054231 A1 AR 054231A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- atom
- heterocyclic residue
- linked
- independently
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 239000007787 solid Substances 0.000 abstract 3
- WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
Abstract
Composiciones farmacéuticas solidas adecuadas para administracion oral, las cuales comprenden un fármaco sensible al agua, de preferencia un derivado de indolil-maleimida, un proceso para su produccion, y uso de las mismas. Reivindicacion 1: Una composicion farmacéutica solida adecuada para administracion oral, la cual comprende un derivado de indolil-maleimida de la formula (1) en donde: Ra es H, alquilo C1-4, o alquilo C1-4 sustituido por OH, NH2, NH-alquilo C1-4, o N-(di-alquilo C1-4)2; Rb es H o alquilo C1-4; R es un radical de la formula (a, (b), (c), (d), (e) o (f); en donde cada uno de R4, R7, R8, R11, y R14 es OH; SH; un residuo heterocíclico; NR16R17, en donde cada uno de R16 y R17 es independientemente H o alquilo C1-4, o R16 y R17 forman, junto con el átomo de N con el que están enlazados, un residuo heterocíclico, o un radical de la formula -X-Rc-Y en donde X es un enlace directo, O, S, o NR18, en donde R18 es H o alquilo C1-4; Rc es alquileno C1-4, o alquileno C1- 4 en donde un CH2 es reemplazado por CRxRy, en donde uno de Rx y Ry es H, y el otro es CH3, cada uno de Rx y Ry es CH3, o Rx y Ry forman juntos -CH2-CH2-, e Y está enlazado al átomo de C terminal, y se selecciona a partir de OH, un residuo heterocíclico, y -NR19R20, en donde cada uno de R19 y R20 es independientemente H, cicloalquilo C3-6, cicloalquilo C3-6-alquilo C1-4, aril-alquilo C1-4, o alquilo C1-4 opcionalmente sustituido sobre el átomo de C terminal por OH, o R19 y R20 forman, junto con el átomo de N con el que están enlazados, un residuo heterocíclico; cada uno de R2, R3, R5, R6, R9, R10, R12, R13, R15, y R'15, es independientemente H, halogeno, alquilo C1-4, CF3, OH, SH, NH2, alcoxilo C1-4, tioalquilo C1-4, NH-alquilo C1-4, N(di-alquilo C1-4)2, o CN; ya sea que E es -N= y G es -CH=, o bien E es -CH= y G es -N=; y el anillo A está opcionalmente sustituido, en forma libre o en forma de sal farmacéuticamente aceptable. Reivindicacion 28: Un uso de una composicion farmacéutica solida adecuada para administracion oral de acuerdo con cualquiera de las reivindicaciones 1 a 23, para la preparacion de un medicamento para la prevencion o el tratamiento de trastornos o enfermedades mediadas por los linfocitos-T y/o PKC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0504203.1A GB0504203D0 (en) | 2005-03-01 | 2005-03-01 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054231A1 true AR054231A1 (es) | 2007-06-13 |
Family
ID=34430431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20060100713A AR054231A1 (es) | 2005-03-01 | 2006-02-27 | Composiciones farmaceuticas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20080187582A1 (es) |
| EP (1) | EP1855667A1 (es) |
| JP (1) | JP2008531625A (es) |
| KR (2) | KR20090097224A (es) |
| CN (1) | CN101132792A (es) |
| AR (1) | AR054231A1 (es) |
| AU (1) | AU2006220056B2 (es) |
| BR (1) | BRPI0607413A2 (es) |
| CA (1) | CA2599196A1 (es) |
| GB (1) | GB0504203D0 (es) |
| GT (1) | GT200600072A (es) |
| IL (1) | IL184847A0 (es) |
| MA (1) | MA29278B1 (es) |
| MX (1) | MX2007010559A (es) |
| NO (1) | NO20074933L (es) |
| PE (1) | PE20061243A1 (es) |
| RU (1) | RU2007136162A (es) |
| TN (1) | TNSN07337A1 (es) |
| TW (1) | TW200700062A (es) |
| WO (1) | WO2006092255A1 (es) |
| ZA (1) | ZA200706192B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| GB0613162D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic compounds |
| CA2658835A1 (en) * | 2006-08-23 | 2008-02-28 | Novartis Ag | Use of pkc inhibitors in ocular diseases |
| AU2007309558B2 (en) * | 2006-10-20 | 2012-05-24 | Novartis Ag | Crystal modifications -3- (1H-indol-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-dione |
| US20100075997A1 (en) * | 2006-12-07 | 2010-03-25 | Alexander Korn | Use of pkc inhibitors in transplantation |
| MX2009009572A (es) * | 2007-03-09 | 2009-12-08 | Novartis Ag | Sales de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-i-il)-quinazoli n-4-il]-pirrole-2, 5-di ona. |
| AR069799A1 (es) * | 2007-12-21 | 2010-02-17 | Novartis Ag | Composicion farmaceutica |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| AR081776A1 (es) * | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| CN109846840B (zh) * | 2018-12-18 | 2021-08-10 | 江西润泽药业有限公司 | 一种血管内皮生长因子抑制剂的固体剂型及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU226821B1 (en) * | 1995-11-20 | 2009-11-30 | Lilly Co Eli | The mesylate salt of a macrocyclic bis-indolyl-maleimide derivative, process for its preparation, use thereof and pharmaceutical compositions containing the same |
| EP1224932A4 (en) * | 1999-08-20 | 2002-10-16 | Sagami Chem Res | ACTIVE SUBSTANCES TO INHIBIT CELL DEATH |
| BRPI0115193B1 (pt) * | 2000-11-07 | 2016-08-09 | Novartis Ag | derivados de indolilmaleimida, processo para preparação dos mesmos, bem como composição farmacêutica que os compreende |
| PE20040079A1 (es) * | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
-
2005
- 2005-03-01 GB GBGB0504203.1A patent/GB0504203D0/en not_active Ceased
-
2006
- 2006-02-15 GT GT200600072A patent/GT200600072A/es unknown
- 2006-02-24 PE PE2006000222A patent/PE20061243A1/es not_active Application Discontinuation
- 2006-02-27 MX MX2007010559A patent/MX2007010559A/es not_active Application Discontinuation
- 2006-02-27 RU RU2007136162/15A patent/RU2007136162A/ru not_active Application Discontinuation
- 2006-02-27 AR AR20060100713A patent/AR054231A1/es not_active Application Discontinuation
- 2006-02-27 WO PCT/EP2006/001767 patent/WO2006092255A1/en not_active Ceased
- 2006-02-27 KR KR1020097018247A patent/KR20090097224A/ko not_active Withdrawn
- 2006-02-27 JP JP2007557400A patent/JP2008531625A/ja active Pending
- 2006-02-27 TW TW095106715A patent/TW200700062A/zh unknown
- 2006-02-27 EP EP06707282A patent/EP1855667A1/en not_active Withdrawn
- 2006-02-27 CN CNA2006800066977A patent/CN101132792A/zh active Pending
- 2006-02-27 AU AU2006220056A patent/AU2006220056B2/en not_active Ceased
- 2006-02-27 KR KR1020077019720A patent/KR20070099049A/ko not_active Ceased
- 2006-02-27 US US11/815,865 patent/US20080187582A1/en not_active Abandoned
- 2006-02-27 BR BRPI0607413-8A patent/BRPI0607413A2/pt not_active IP Right Cessation
- 2006-02-27 CA CA002599196A patent/CA2599196A1/en not_active Abandoned
-
2007
- 2007-07-26 IL IL184847A patent/IL184847A0/en unknown
- 2007-07-26 ZA ZA200706192A patent/ZA200706192B/en unknown
- 2007-08-31 TN TNP2007000337A patent/TNSN07337A1/en unknown
- 2007-08-31 MA MA30179A patent/MA29278B1/fr unknown
- 2007-09-28 NO NO20074933A patent/NO20074933L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20080187582A1 (en) | 2008-08-07 |
| BRPI0607413A2 (pt) | 2009-09-01 |
| TNSN07337A1 (en) | 2008-12-31 |
| ZA200706192B (en) | 2008-07-30 |
| EP1855667A1 (en) | 2007-11-21 |
| NO20074933L (no) | 2007-09-28 |
| RU2007136162A (ru) | 2009-04-10 |
| AU2006220056B2 (en) | 2009-12-10 |
| KR20090097224A (ko) | 2009-09-15 |
| MX2007010559A (es) | 2007-10-03 |
| JP2008531625A (ja) | 2008-08-14 |
| GT200600072A (es) | 2006-10-09 |
| AU2006220056A1 (en) | 2006-09-08 |
| WO2006092255A1 (en) | 2006-09-08 |
| CN101132792A (zh) | 2008-02-27 |
| GB0504203D0 (en) | 2005-04-06 |
| IL184847A0 (en) | 2007-12-03 |
| MA29278B1 (fr) | 2008-02-01 |
| KR20070099049A (ko) | 2007-10-08 |
| PE20061243A1 (es) | 2006-12-21 |
| TW200700062A (en) | 2007-01-01 |
| CA2599196A1 (en) | 2006-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035211A1 (es) | Derivados de indolilmaleimida, un proceso para su preparacion, una composicion farmaceutica y una combinacion que los comprenden | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR061101A1 (es) | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR025735A1 (es) | Compuestos terapeuticos | |
| MA34604B1 (fr) | Derives de la pyrazine en tant que bloqueurs de l'enac | |
| AR051090A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR051091A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| AR064874A1 (es) | Derivados de hexahidro y tetrahidropterinas,composiciones farmaceuticas que los contienen y usos de las mismas en trastornos cardiovasculares y psiquiatricos entre otros | |
| AR076859A1 (es) | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| AR054231A1 (es) | Composiciones farmaceuticas | |
| AR046452A1 (es) | Derivados de quinazolina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento con efecto antiproliferativo | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR031715A1 (es) | Compuestos derivados de tetrahidro-heterociclo-acepinil-pirimidina, uso de los mismos, un procedimiento para fabricarlos y medicamentos que los comprenden | |
| AR060535A1 (es) | Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina | |
| AR049372A1 (es) | Compuestos biciclicos de amina y composiciones farmaceuticas que los comprenden | |
| AR043181A1 (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6 | |
| TW200612936A (en) | Indole derivatives | |
| AR036905A1 (es) | Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis | |
| AR062405A1 (es) | Derivados de isoindol | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| AR056198A1 (es) | Un proceso para la fabricacion de una composicion farmaceutica tipo tableta | |
| AR048808A1 (es) | Pirrolocarbazoles fusionados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |